Summary and next episodes
Prof. Ulrich Laufs and Dr Robert P. Giugliano join us direct from AHA 2025 to share their key lipid management highlights and provide insights into how new data from the VESALIUS-CV, VESALIUS-REAL, CORE-TIMI 72a/CORE2-TIMI 72b trials, and trials investigating CTX310 and DR10624 could impact clinical practice.
- VESALIUS-CV: Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
- VESALIUS-REAL: Stroke and Myocardial Infarction Rates in Patients at High Risk for a First ASCVD Event
- CORE-TIMI 72a and CORE2-TIMI 72b: Olezarsen in Patients with Severe Hypertriglyceridemia
- Targeting ANGPTL3: First-in-Human Phase 1 Clinical Trial of a CRISPR-Cas9 Gene Editing Therapy
- DR10624: A First-In-Class, FGF21 Receptor/Glucagon Receptor/GLP-1 Receptor Triple Agonist
Watch the video for expert insights into what these data could mean for lipid management.
Clinical takeaways
- In high-risk patients without prior MI or stroke, sustained evolocumab therapy produced substantial LDL-C reductions—often approaching ~1.0 mmol/L (~40 mg/dL)—and was associated with fewer first major cardiovascular events and improved long-term morbidity; Real world evidence supports the real-world translatability of this strategy and highlights persistent undertreatment, favouring earlier escalation when LDL-C remains above target on maximally tolerated statin ± ezetimibe
- Targeted ApoC-III inhibition delivers substantial, durable triglyceride lowering in severe hypertriglyceridaemia to support pancreatitis-risk mitigation, with a manageable safety profile in which platelet monitoring is prudent given class history, but current signals appear lower than earlier ApoC-III inhibitors
- The investigational triple agonist DR10624 shows concurrent improvements in triglycerides, atherogenic lipids and hepatic steatosis, suggesting potential for integrated management, with early tolerability chiefly gastrointestinal and the need for longer-term hepatic/metabolic monitoring
- Single-dose in vivo gene editing yields durable reductions in LDL-C and triglycerides for selected high-risk dyslipidaemia, with manageable early safety
Duration
Language(s)
15 MIN
Oct 2023 
Downloadable 
